Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...